MDL Isentris Platform Selected by LEO Pharma
News Dec 22, 2005
As the first open-standards-based, n-tier discovery informatics platform designed for life sciences researchers, Isentris is effectively integrating the data and workflow applications scientists use every day and promoting a self-service research environment to enhance decision making and improve R&D productivity.
"LEO Pharma is a global company committed to developing innovative and efficacious products and associated services," said Karsten Linneberg, head of section, R&D IT, department of spectroscopy 751, LEO Pharma.
"As such, we are continually seeking to improve the day-to-day efficiency and productivity of our R&D teams."
"By playing a central role in integrating data and workflow applications and fostering knowledge-driven decisions, Isentris will accelerate and streamline LEO Pharma's intensive R&D activities."
"The complete MDL Isentris platform offers research organizations a clear path to better decisions, shorter cycle times and a higher return on investment," said Lars Barfod, president & chief executive officer of Elsevier MDL.
"We are delighted that LEO Pharma has elected to migrate from MDL® ISIS to the full suite of next-generation MDL Isentris products."
"This is further confirmation that Isentris is being accepted as the integrated informatics platform of choice for life sciences R&D organizations."
The MDL Isentris platform includes the MDL® Base user interface, MDL® Draw chemical drawing and rendering software, MDL® Core Interface middle tier with Integrating Data Source and the MDL® Direct chemical data cartridges for molecules and reactions.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE